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Human papillomavirus-like particles (HPV VLP) are candidate vaccines that have shown to be efficacious in reducing infection and inducing
robust antiviral immunity. Neutralizing antibodies generated by vaccination are largely type-specific, but little is known about the type-specificity
of cellular immune responses to VLP vaccination. To determine whether vaccination with HPV-16 L1VLP induces cellular immunity to
heterologous HPV types (HPV-18, HPV-31, and HPV-53), we examined proliferative and cytokine responses in vaccine (n=11) and placebo
(n=5) recipients. Increased proliferative and cytokine responses to heterologous types were observed postvaccination in some individuals. The
proportion of women responding to heterologous types postvaccination (36%–55%) was lower than that observed in response to HPV-16 (73%).
Response to HPV-16 VLP predicted response to other types. The strongest correlations in response were observed between HPV-16 and HPV-31,
consistent with their phylogenetic relatedness. In summary, PBMC from HPV-16 VLP vaccine recipients can respond to L1VLP from
heterologous HPV types, suggesting the presence of conserved T cell epitopes.
© 2006 Elsevier Inc. All rights reserved.Keywords: T cells; Cytokines; Vaccination; Infectious diseasesIntroduction
Infection with one of approximately 15 HPV types is now
recognized as the necessary cause of cervical cancer (Bosch et
al., 1995; Walboomers et al., 1999). Two of these HPV types,
HPV-16 and HPV-18, account for 60–70% of all cervical cancer
cases worldwide (Ho et al., 1998; Munoz et al., 2003). Vaccines
containing virus-like particles (VLP) from these two HPV types⁎ Corresponding author. HPV Immunology Laboratory, SAIC-Frederick/NCI-
Frederick, Building 469, Room 120, Frederick, MD 21702, USA. Fax: +1 301
846 6954.
E-mail address: lpinto@ncifcrf.gov (L.A. Pinto).
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doi:10.1016/j.virol.2006.06.021have been shown to be well tolerated and provide strong short-
term protection against transient and persistent HPV-16 and
HPV-18 infections (Harper et al., 2004; Harro et al., 2001;
Koutsky et al., 2002; Villa et al., 2005). These findings support
the notion that cervical cancer might be preventable through
vaccination.
High levels of neutralizing antibodies generated after
vaccination are believed to be the primary effector of protection
conferred by HPV VLP vaccination (Harro et al., 2001; Suzich
et al., 1995). These neutralizing antibodies to L1 are
predominantly type-specific, with the exception of very closely
related types which show weak cross-reactivity (Christensen
and Kreider, 1990; Roden et al., 1996a, 1996b). Furthermore, in
452 L.A. Pinto et al. / Virology 353 (2006) 451–462animal studies, vaccination with VLP or virions derived from
one papillomavirus type does not protect against experimental
infection with heterologous types, indicating that protection is
type-specific (Breitburd et al., 1995; Roden et al., 1996a,
1996b). This leads to the idea that effective prophylactic HPV
vaccines should be polyvalent and contain the HPV types
responsible for most cervical cancers.
In addition to neutralizing antibodies, HPV 16 L1 VLP
vaccination has been shown to induce L1-specific T cell
responses detectable by proliferation of both CD4 and CD8 T
cells and in vitro production of Th1 and Th2 type cytokines
(Pinto et al., 2003). The role these responses may play in the
prophylactic efficacy of HPV VLP vaccines remains to be
elucidated. However, data suggest that CD4 T cells are
important for both the induction and maintenance of humoral
responses (Yao et al., 2004; Zinkernagel et al., 1996), and might
therefore contribute to the efficacy of HPV VLP vaccines. In
addition, a protective effect of HPV-16/18 VLP vaccination
against infection with other oncogenic HPV types was recently
reported (Harper et al., 2006). Natural infection-induced T cell
responses to HPV-11, in contrast to antibody responses, have
been reported to cross-react with a range of HPV types
(Williams et al., 2002). Such cross-reactive T cell responses in
the presence of strain-specific antibody responses are a feature
of other human viral infections, most notably influenza virus
infection (Gelder et al., 1995). Cross-reactive immune
responses to heterologous HPV types may be of significance
for HPV vaccine strategies and may influence protection against
heterologous HPV types.
Finally, little is known about the possible efficacy of HPV
VLP vaccines in treating established infections. Animal studies
have suggested that L1 VLP vaccination does not induce
regression of established papillomas, but provided some
evidence that vaccination leads to a reduction in the mean
number of lesions observed (Kirnbauer et al., 1996). Further-
more, in one human trial, there is preliminary evidence
suggesting that vaccination with HPV-6 VLPs might have a
therapeutic effect against genital warts (Zhang et al., 2000).
HPV-16 L1-specific T cell epitopes elicited by vaccination have
not yet been described and it is not known whether vaccination
with HPV-16 L1 VLP induces cellular immune reactivity to
other HPV types.
To better understand whether vaccination with HPV-16
L1 VLP induces immune responses against heterologous
HPV types, we evaluated proliferative and cytokine (IFN-γ,
IL-10, and IL-5) responses to L1 VLP from heterologous
HPV types in vitro before and following intramuscular
vaccination of healthy young women. We selected as
heterologous HPV types of interest HPV-18, HPV-31, andFig. 1. Lymphoproliferative responses to HPV-16 L1 VLP and VLPs from heterolo
n=5) recipients. PBMCs collected before and after immunization (month 2 and 7)
(0.1 μg/ml) or the recall antigen influenza virus (flu, 1:100). Proliferative responses we
method. Responses are expressed as stimulation indices (S.I.) calculated by dividing
background cultures. Median cpm of media background cultures at month 0, 2, and
recipients were 628, 801, and 982, respectively. * indicates p<0.05 determined usi
month 2 or 7 with median proliferative responses at month 0 for each of the antigenHPV-53 because of the availability of VLP from these types
and also the fact that they represent a broad spectrum of
HPV types, including an HPV type within the same species
group as HPV-16 (HPV-31), a more distant oncogenic HPV
type (HPV-18), and a common non-oncogenic HPV type
(HPV-53).
Results
Cellular immune responses to HPV-16 and heterologous-type
VLPs following immunization with HPV-16 VLP
Lymphoproliferative responses to HPV VLPs from various
HPV types (HPV-16, -18, -31, and -53) were evaluated before
and after vaccination with HPV-16 VLP (Fig. 1). Consistent
with our previous publication (Pinto et al., 2003), increases in
proliferative responses to HPV-16 VLP were observed follow-
ing vaccination in most vaccine recipients (Fig. 1A) but not in
placebo recipients (Fig. 1G). Median proliferative responses to
the heterologous HPV VLPs (18, 31, and 53) were increased
after vaccination with HPV-16 L1 VLP (Figs. 1B–F) when
compared to responses before vaccination. However, most
differences were not statistically significant because increased
responses to heterologous VLPs were only seen in some vaccine
recipients following vaccination with HPV-16 VLP. No
significant increases in lymphoproliferative responses were
observed over time for influenza or at month 2 for the control
lysate (Figs. 1F and E). At month 7, there was evidence of an
increase in lymphoproliferative response for the control lysate,
but the median response was below what is typically considered
a positive response (SI<2.0).
When the group of women who received placebo was
evaluated, there was no evidence of proliferative response to
HPV-16, HPV-18, HPV-31, or HPV-53 VLP postvaccination
(Figs. 1G–L).
Next, cytokine levels produced by PBMC from vaccine and
placebo recipients in response to stimulation with HPV-16 L1
VLP and VLP from the heterologous HPV types were
evaluated. Consistent with our previous report (Pinto et al.,
2003), increases in cytokine production levels by PBMC in
response to HPV-16 VLP were observed following vaccina-
tion. We observed a tendency for IFN-γ responses to all three
heterologous HPV VLP to increase following vaccination,
although the effects did not reach statistical significance for all
VLPs because responses were only seen in some individuals
(Figs. 2A–D). As seen with proliferative responses, median
IFN-γ responses were strongest at month 2 after first
vaccination. At month 2, a 2.6-fold, 3.6-fold, and 4.1-fold
increase over prevaccination levels was observed for HPV-18,gous types (HPV-18, -31, and -53) in vaccine (A–F, n=11) and placebo (G–L,
were stimulated in the presence of HPV VLPs (2.5 μg/ml) or a control lysate
re evaluated on day 5 after stimulation by a standard 3H-thymidine incorporation
the cpm values of cultures in the presence with antigen by cpm values of media
7 for vaccine recipients were 621, 610, and 529, respectively and for placebo
ng Wilcoxon signed rank test to compare the median proliferative responses at
s within vaccine or placebo recipients.
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455L.A. Pinto et al. / Virology 353 (2006) 451–462HPV-31, and HPV-53, respectively (Figs. 2B–D) compared to
a median increase of 8.9-fold for HPV-16 (Fig. 2A). No
increases in median levels of IFN-γ responses were observed
over time to influenza or to the control lysate (Figs. 2F and E).
No increases in median levels IFN-γ production were
observed in placebo recipients in response to any of the
heterologous HPV VLPs evaluated (Figs. 2G–J). Patterns of
IL-10 responses to heterologous HPV VLPs were overall
similar to those seen with IFN-γ, with the exception of
responses to HPV-18 which were not found to be elevated at
month 2 following vaccination among individuals who received
the HPV-16 VLP vaccine (data not shown). No remarkable
increases in IL-5 production were observed at month 2 or 7 in
PBMC from vaccine recipients in response to any of the three
heterologous HPV VLPs in vaccine recipients (data not shown).
In general, placebo recipients did not show responses to the
VLPs by the various assays, with the exception of a single
individual receiving placebo that exhibited a significant
increase in the IL-10 response to HPV-18 VLP (111.3 pg/ml
at month 2 compared to 17.2 pg/ml at month 0).
Based on the increase in T cell responses after vaccination,
subjects were divided into two groups: vaccine responders and
non-responders. Responders were those who had: (1) at least a
2-fold increase in response to VLPs when comparing immune
response at baseline (month 0) with responses after vaccination;
(2) lymphoproliferative response to VLPs that was positive
(SI>2.0) when compared to media or twice the lowest
detectable level of the assay (for cytokines), and (3) ratio of
responses at month 2/month 0 for VLP greater than that for the
control lysate.
Consistent with our previous publication, 73% of vacci-
nated women showed evidence of lymphoproliferative
response to HPV-16 VLP postvaccination (Table 1) (median
increase in response postvaccination among responders=5.6-
fold; median response=SI of 18.0). 64% of vaccinated
women produced increased amounts of IFN-γ and IL-10 in
response to HPV-16 VLP postvaccination (median increases
in response postvaccination among responders=8.9-fold and
7.4-fold for IFN-γ and IL-10, respectively; median
responses=82.9 pg/ml for IFN-γ and 36.6 pg/ml for IL-10).
Also consistent with our previous report, increases in the level
of IL-5 production in response to HPV-16 VLP postvaccina-
tion were observed in only 36% of vaccinated women
(median increases in response postvaccination among respon-
ders=17.5-fold; median response=56.2 pg/ml). Nearly half
(45%) of vaccinated women responded to HPV-16 VLP
postvaccination by all three assays, lymphoproliferation, IFN-
γ, and IL-10 production. There was little evidence of
increasing responses to influenza after vaccination, suggesting
that the responses to HPV antigens seen postvaccination were
specific (Table 1).Fig. 2. Cytokine (IFN-γ) responses to HPV-16 L1 VLP and VLPs from heterologou
PBMC collected before and after immunization (month 2 and 7) were stimulated in t
antigen influenza virus (flu, 1:100) for 3 days. Cytokine levels were determined by EL
duplicate. * indicates p<0.05 determined using Wilcoxon signed rank test to compa
responses at month 0 for each of the antigens within vaccine or placebo recipients.Responses to heterologous HPV VLP types were also
observed among vaccinated women. The proportion of
vaccinated women who developed T cell responses to
heterologous HPV types was lower than that observed for
HPV-16 VLP (Table 1). Between 36% (for HPV-18 and HPV-
53) and 55% (for HPV-31) of vaccinated women had evidence
of a lymphoproliferative response to heterologous HPV types
postvaccination. A subset of vaccinated women was also found
to produce IFN-γ and IL-10 in response to heterologous HPV
types postvaccination (Table 1). The weakest responses were, in
general, observed for HPV-18. Few women were defined as
responders based on the IL-5 assay, consistent with the modest
IL-5 responses seen for HPV-16. Results from the IL-5 assay
were therefore not considered in further analyses. 33% of
vaccinated women responded to HPV-31 VLP postvaccination
by the lymphoproliferation, IFN-γ, and IL-10 assays. The
percentages for HPV-18 and HPV-53 were 0% and 22%,
respectively.
Immune response to HPV-16 VLP predicts response to
heterologous VLPs
Next, we evaluated the proportion of vaccinated women who
responded to multiple heterologous HPV types (Table 2). 45%
of vaccinated women had evidence of response to more than
one heterologous HPV type postvaccination, as measured by the
lymphoproliferation assay. 18% responded to all three hetero-
logous types evaluated in our study. The comparable rates
(response to >1 type/response to all 3 types) based on IFN-γ
and IL-10 measures were 25%/12.5% and 12.5%/0%, respec-
tively. Interestingly, none of the vaccinated women who were
non-responders to HPV-16 VLP postvaccination were observed
to respond to >1 heterologous HPV type, while a substantial
fraction of vaccinated women who responded to HPV-16 VLP
postvaccination also responded to multiple heterologous HPV
types (Table 2).
When the correlation between intensity of response to HPV-
16 VLP postvaccination and response to each of the hetero-
logous HPV types was evaluated, the strongest correlations
(range 0.73–0.84) were observed between HPV-16 and HPV-31
for all three assays (Table 3). Significant correlations were also
observed between HPV-16 and HPV-53 for the three assays. In
general, weaker correlations were observed between responses
to HPV-16 VLP and HPV-18 VLP, likely due to the high
background responses observed against HPV-18 VLP. Correla-
tions among heterologous types themselves (i.e., between HPV-
18, HPV-31, and HPV-53 responses) were also observed and
ranged from 0.47 (HPV-18: HPV-53) to 0.77 (HPV-31: HPV-
53) for lymphoproliferation, 0.3 (HPV-18: HPV-31) to 0.58
(HPV-31: HPV-53) for IFN-γ, and were from − 0.08 (HPV-31:
HPV-18) to 0.38 (HPV-31: HPV-53) for IL-10. Individuals withs types (HPV-18, -31, and -53) in vaccine (A–F) and placebo (G–L) recipients.
he presence of HPV VLPs (2.5 μg/ml), a control lysate (0.1 μg/ml) or the recall
ISA in culture supernatants. Results are expressed as pg/ml of cultures tested in
re the median proliferative responses at month 2 or 7 with median proliferative
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Table 2
Distribution of lymphoproliferative and cytokine responses to multiple
heterologous HPV types after vaccination with HPV-16 VLP-overall and
stratified by response to HPV-16 VLP a
N % responding to >1
heterologous HPV types
% responding to all 3
heterologous HPV types
Lymphoproliferation
All vaccinees 11 45.0 18.0
HPV-16 non-
responders
3 0.0 0.0
HPV-16
responders
8 62.5 25.0
p value 0.18 0.56
IFN-γ
All vaccinees 8 25.0 12.5
HPV-16 non-
responders
3 0.0 0.0
HPV-16
responders
5 40.0 20.0
p value 0.46 1.00
IL-10
All vaccinees 8 12.5 0.0
HPV-16 non-
responders
3 0.0 0.0
HPV-16
responders
5 20.0 0.0
p value 1.00 1.00
The percent of women responding to more than one heterologous HPV type was
compared between responders and non-responders to HPV-16 VLP; p values
were obtained based on the Fisher's exact test.
a In some instances, the total number of women evaluated is <11 due to
insufficient material available for assay.
456 L.A. Pinto et al. / Virology 353 (2006) 451–462the highest increases in proliferative responses to HPV-16 had
higher average increases to any of the heterologous HPV VLP
tested.
No significant correlations were observed between antibody
titers and proliferation or IFN-γ responses to any of the HPV
types following vaccination. The largest correlation with
antibody titers was found for IL-10 response to HPV-16 L1
VLP (r=0.53; p=0.01). In addition, antibody titers to HPV-16
correlated strongly with HPV-31 neutralizing activity (r=0.891,
p=0.0048), although the HPV-31 neutralizing titers were
markedly lower than the HPV-16 titers following vaccination
(Table 4) and were only detected in some of the vaccine
recipients.
Patterns of response to heterologous VLPs
Patterns of lymphoproliferative responses to heterologous
HPV VLP among individuals classified as responders are
shown in Fig. 3. Patterns of response to HPV-16 VLP are also
presented for comparison. Responses to heterologous HPV
VLP were typically lower than those observed against HPV-16
VLP. Response patterns varied between individuals and were
most variable at month 7 (one month following the third
immunization). While the strongest increases in response were
typically observed at month 2 (one month following second
immunization), additional increases in response were seen at
Table 3
Correlation between responses to HPV-16 VLP and VLPs from heterologous types at months 2 and 7
Assay HPV type VLP HPV-18 HPV-31 HPV-53 HPV-16 Ab
Proliferation HPV-16 0.61 (p=0.003) 0.76 (p<0.0001) 0.73 (p=0.0001) 0.25 (p=0.26)
HPV-18 – 0.53 (p=0.01) 0.47 (p=0.03) −0.19 (p=0.39)
HPV-31 – – 0.77 (p<0.0001) 0.07 (p=0.77)
HPV-53 0.31 (p=0.17)
IFN-γ HPV-16 0.31 (p=0.16) 0.84 (p=0.0001) 0.76 (p=0.0001) 0.36 (p=0.10)
HPV-18 – 0.30 (p=0.18) 0.57 (p=0.007) 0.11 (p=0.63)
HPV-31 – – 0.58 (p=0.008) 0.41 (p=0.068)
HPV-53 0.068 (p=0.77)
IL-10 HPV-16 0.17 (p=0.45) 0.73 (p=0.0002) 0.68 (p=0.0007) 0.53 (p=0.01)
HPV-18 – − 0.08 (p=0.71) 0.03 (p=0.91) 0.08 (p=0.73)
HPV-31 – – 0.38 (p=0.10) 0.35 (p=0.12)
HPV-53 −0.03 (p=0.90)
To analyze the relationships between responses to different VLPs, Spearman rank correlations for continuous values were determined. A p value <0.05 was considered
significant.
457L.A. Pinto et al. / Virology 353 (2006) 451–462month 7 for HPV-16 VLP in 75% of responders and for
heterologous types in 25% (HPV-18) to 67% (HPV-31) of
responders. Of the non-responders at month 2, 67% showed
increased lymphoproliferative response to HPV-16 at month 7.
However, none of the non-responders at month 2 met our
criteria for responses to heterologous VLP at month 7. A similar
pattern of variability was seen in cytokine responses to the
heterologous VLP (data not shown).
Lymphoprolliferative response to HPV-16 and heterologous
HPV type VLPs includes both CD4 and CD8 T cells
To determine the contribution of CD4 and CD8 T cells in the
proliferative responses to VLPs detected after immunization,
incorporation of the thymidine analog BrdU was used to
measure the relative numbers of CD4 and CD8 T cells
progressing through S phase of the cell cycle after in vitro
stimulation with the different L1 VLPs. BrdU incorporation into
the DNA of CD4 and CD8 T cells was quantified by flow
cytometry. Consistent with our previous publication (Pinto et
al., 2003), increased levels of proliferating CD4 and CD8 Tcells
in response to HPV-16 L1 VLP were observed in an
independent subset of 6 vaccine recipients tested (Table 5).
As previously seen in response to HPV-16 L1VLPs, responses
to the heterologous types (HPV-18, -31, and -53) were also seen
in CD4 and CD8 T cells. The level of response to L1 VLPs wasTable 4
Mean antibody titers at month 0, 2, and 7 in vaccine recipients (n=11)
Mean antibody titers (median)
Month 0 Month 2 Month 7
HPV-16 28±94 (0) 6927±16,699 (511.4) 12,663±15,060 (4929)
HPV-18 0 (0) 0 (0) 0 (0)
HPV-31 4±14 (0) 35.6±73.4 (0) 250±438 (50)
BPV 0 (0) 0 (0) 0 (0)
All placebo recipients (n=5) had mean titers of 0 at any time post vaccination to
any of the HPV types.
Titers were determined using a pseudovirus neutralization assay, as described in
Materials and methods.higher among CD4 T cells than among CD8 T cells for HPV-16,
-18, and -31 and was similar in both subsets for HPV-53 VLPs.
Discussion
The current results indicate the presence of cross-reactive T
cell responses to HPV types in individuals immunized with a
monovalent HPV-16 L1 VLP vaccine. PBMC from HPV-16 L1
VLP vaccine recipients showed proliferative (in CD4 and CD8
Tcells) and cytokine responses in vitro to L1 VLP from an HPV
type that closely resembles HPV-16 (HPV-31), and oncogenic
(HPV-18) and non-oncogenic (HPV-53) types that are more
distantly related to HPV-16. The proportion of women
responding to heterologous HPV VLPs postvaccination was
lower than observed for HPV-16 VLP and the patterns of
response varied among responders. Response to HPV-16 VLP
was predictive of response to heterologous VLP.
As previously reported (Pastrana et al., 2004), sera from
HPV-16 L1 vaccine recipients had significant anti-HPV-16
neutralizing titers and no HPV-18 neutralizing activity follow-
ing immunization. HPV-31 neutralizing activity was weak,
detected only in a fraction of the vaccine recipients following
vaccination and correlated with HPV-16 neutralizing titers.
Cross-protection between HPV types with vaccines based on
the HPV L1 antigen has been considered unlikely, since
neutralizing antibodies induced by L1 VLP have been shown to
be primarily type-specific in animal models (Breitburd et al.,
1995; Roden et al., 1996a, 1996b). Type-specific responses with
some cross-reactivity between phylogenetically related types
have been shown in studies of natural infection (Combita et al.,
2002; Marais et al., 2000; Wideroff et al., 1999).
The data shown here raise the intriguing possibility that by
vaccinating with a limited number of HPV types, one might be
able to induce immune responses to a broader set of HPV types,
and that this response might in turn be involved in protection
against heterologous HPV infections. Consistent with this
possibility, cross-protection against incident infection with
heterologous HPV types (HPV-31 and HPV-45) following
vaccination with a bivalent HPV-16/18 VLP vaccine was
recently published (Harper et al., 2006). Although the
Fig. 3. Lymphoproliferative responses to HPV-16, -18, -31, and -53 VLPs before and over time after vaccination with HPV-16 L1 VLPs among responders. All vaccine
recipients were tested but only responders to respective VLPs are shown. Results are expressed as Stimulation Indices (SI). Responders were classified as defined in
Materials and methods. PBMC were cultured for 5 days in the presence of each of the antigens and proliferation was determined using a standard 3H-thymidine
incorporation method, as indicated in Materials and methods.
458 L.A. Pinto et al. / Virology 353 (2006) 451–462mechanism of cross-protection has not been yet determined, it is
possible that a strong antibody and cellular immune response
may contribute to this in vivo effect.
While sterilizing immunity mediated by neutralizing antibody
responses remains the main goal for prophylactic HPV vaccina-
tion, cell-mediated immune responses should not be overlooked.
CD4 T cell responses have been shown to play a role in the
induction and maintenance of humoral responses (Yao et al.,
2004; Zinkernagel et al., 1996) and CD4 and CD8 T cells or
cytokines induced by HPV VLP vaccination (Emeny et al., 2002;
Pinto et al., 2003) might well be capable of targeting HPV-
infected cells, thereby potentially participating in the clinical
benefit fromHPVVLP vaccination. Future evaluation, in ongoing
large-scale HPV VLP vaccine trials, of the efficacy of HPV VLP
vaccination in the eradication of prevalent HPV infection is
needed to directly address this possibility. Several questions
remain to be answered, including: (1) whether cross-reactive T
help induced by the vaccine would help in the rapid induction of
an antibody response to infection by an heterologous HPV type;
(2) whether T cell responses against the L1 protein of HPV can
effectively target HPV infections at the basal layer of the
epithelium, where levels of L1 expression are typically below
detectable levels (De Bruijn et al., 1998; Firzlaff et al., 1988); (3)
whether the levels of response demonstrated herein are sufficient
to induce protection, and if so to what HPV types.
Responses to VLPs from heterologous types following
immunization were in general weaker and more variable than
those seen for HPV-16 VLP. Nevertheless, responses to HPV-31
correlated with responses to HPV-16 VLP (Table 3). HPV-31 is
the most closely related heterologous HPV type to HPV-16investigated, having approximately 83% homology (Chan et al.,
1995; Roden et al., 1996a, 1996b). A significant correlation was
also seen between HPV-16 L1 and HPV-53 VLP cellular
immune responses, consistent with the fact that L1 shares
substantial sequence homology between different HPV types
and therefore, it is possible that T cell epitopes may be common
across serologically distinct types (Chan et al., 1995; Roden et
al., 1996a, 1996b). Weaker correlations were seen between
HPV-18 and HPV-16. This reduced correlation might be
explained by the high baseline responses to HPV-18 VLP,
which made difficult the evaluation of changes over time for
this VLP type. These high background responses may be related
to the presence of contaminants from the system of production
that were not present in the lysate controls used. Alternatively,
responses may be related to a general immunogenicity of the
HPV-18 VLP structure (Rudolf et al., 2001) or to previous T cell
priming after exposure to the virus in some instances. The
inclusion of additional controls for the system of VLP
production, such as VLPs from unrelated viruses produced in
a similar system may be of interest in future studies.
The inter-individual differences in the ability to respond to
VLPs from different HPV types could be due to HLA
differences. We did not see any clear patterns between responses
and HLA class I or class II haplotypes (data not shown) but the
number of individuals studied here was too small to address this
possibility adequately. Alternatively, differences in T cell
reactivity may be explained by differences in exposure to
microbial antigens. The T cell repertoire available at the time of
viral infection may affect the response to a particular virus
(Welsh et al., 2004). Recent studies have revealed that each
Table 5
Percentage of proliferating (BrdU+) cells within CD4 and CD8, CD3
lymphocytes from vaccine recipients in response to HPV VLPs before and
after immunization
Time a Condition %CD3+CD4+BrdU+
(mean+SD, %, n=6)
%CD3+CD8+BrdU+
(mean+SD, %, n=6)
Pre Media 0.017±0.028 0.025±0.022
HPV-16
VLP
0.022±0.023 0.005±0.008
HPV-18
VLP
0.369±0.210 0.474±0.446
HPV-31
VLP
0.016±0.017 0.001±0.003
HPV-53
VLP
0.144±0.188 0.215±0.402
Control
lysate
0.011±0.012 0.018±0.021
Post Media 0.023±0.0024 0.017±0.010
HPV-16
VLP
1.293±1.285 0.474±0.447
HPV-18
VLP
1.605±0.92 0.801±0.361
HPV-31
VLP
0.157±0.224 0.110±0.153
HPV-53
VLP
0.793±0.699 0.767±0.442
Control
lysate
0.032±0.035 0.028±0.021
Percentages were determined as described in Materials and methods.
a Time of PBMC collection, before (pre) or after (post) immunization
(months 2 or 7).
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which shape the quality and quantity of the memory T cell pool.
This preexisting T cell (memory) pool (Selin et al., 1994;
Stockinger et al., 2004) may be activated and expanded by
subsequent viral infections.
Consistent with previous findings (Pinto et al., 2003), the
highest increments in responses were seen after the second
immunization (i.e., at month 2). In a sizeable subset of
individuals with evidence of increased response after the
second immunization, however, further increases were observed
one month following the third immunization. These results
suggest that repeated immunizations might be effective at
boosting cellular immune responses in a subset of recipients.
Determinants of whether or not a vaccine recipient is likely to
benefit from multiple booster immunizations are currently not
known and will be of interest to investigate should ongoing
trials indicate that HPV VLP-based vaccines can effectively
target established HPV infections.
This is the first demonstration of generation of in vitro cross-
reactive cellular immune responses to heterologous HPV types
in individuals vaccinated with an HPV-16 L1 VLP vaccine.
Cross-reactive lymphoproliferative responses to HPV-6 and
HPV-16 have previously been reported in individuals vacci-
nated with HPV-11 VLP (Evans et al., 2001). This accumulating
data suggest the presence of conserved T cell epitopes in L1
across serologically distinct HPV types. Larger studies are
needed to identify specific L1 epitopes common across HPV
types, and to evaluate the potential role of L1-directed T cellresponses in the induction and maintenance of neutralizing
humoral responses and in the resolution of established HPV
infections.
Materials and methods
Study design
Details of the study design have previously been reported
(Pinto et al., 2003). In brief, a double-blind, randomized,
placebo-controlled phase II trial was conducted at The John
Hopkins University Center for Immunization Research (Balti-
more, MD) to examine the safety and immunogenicity of three
intramuscular injections (at 0, 1, and 6 months) of 50 μg of the
L1 HPV-16 VLP vaccine, without adjuvant, in a group of
healthy female volunteers 18–25 years of age who reported no
more than four sexual partners in their lifetime. Subjects were
evaluated clinically and blood specimens were collected prior to
the initial vaccination (month 0) and 1 month following each
subsequent vaccination (months 2 and 7). The vaccine was well
tolerated and consistently induced high levels of antibodies, as
reported previously (Harro et al., 2001).
The protocol for this study was approved by The John
Hopkins University Institutional Review Board. The blood
specimens earmarked for cell-mediated assays were shipped
fresh to the monitoring laboratory where peripheral blood
mononuclear cells (PBMC) were separated by density centri-
fugation over a Ficoll–Hypaque gradient and cryopreserved.
Cryopreserved PBMC were available for the present study from
16 participants (11 vaccine and 5 placebo recipients).
HPV VLPs
Recombinant human papillomavirus (HPV) type 16 L1
virus-like particles (VLPs) expressed in the baculovirus system
were used to investigate the cellular immune response to VLP
vaccination. HPV-16 L1 VLP used for vaccination was
expressed in baculovirus-infected Sf9 insect cells (Novavax,
Rockville, MD), in accordance to GMP guidelines, as
previously reported (Harro et al., 2001). The HPV VLPs used
for in vitro assessment of CMI were produced by Dr. Viscidi
(JHU) in insect cells (High Five, Invitrogen, Carlsbad, CA)
from recombinant baculovirus expressing the L1 gene of HPV-
18 and 53 and L1 and L2 of HPV-31, as previously described
(Viscidi et al., 2003).
Lymphoproliferation assays
Lymphoproliferation assays were performed on cryopre-
served PBMC collected before (month 0) and after (months 2
and 7) vaccination from a total of 11 vaccine and 5 placebo
recipients (Harro et al., 2001). PBMC were plated in triplicate at
2×105 cells per well in 96 well round bottom plates (Costar,
Cambridge, MA) AIM-V serum-free media (Gibco, Invitrogen).
Cells were cultured in the presence or absence of VLPs from
HPV-16, -18, -31, and -53 (2.5 μg/ml) diluted AIM-V serum-
free media. Stocks of VLP preparations were provided from the
460 L.A. Pinto et al. / Virology 353 (2006) 451–462vaccine manufacturer to the laboratory at 0.8 mg/ml and
1.0 mg/ml. The purity of the HPV-16 VLPs was >96% as
determined by SDS-PAGE. PHA (1:100, Sigma, St. Louis, MO)
and influenza virus (1:100, ATCC, Manassas, VA) were used as
controls for the assay. Cultures containing mitogens or antigens
were pulsed with 1 μCi of 3H-thymidine (Perkin Elmer,
Wellesley, MA) for 18 h after 48 or 96 h of culture, respectively.
Cultures were harvested and counted in an automated scintilla-
tion counter (Microbeta, Perkin Elmer). Results were expressed
as cpm or stimulation indices (S.I.) determined as: cpm of
cultures in the presence of antigen or mitogens/cpm of cultures
in the presence of media alone.
Because the VLPs were purified from a baculovirus
expression system, a Sf-9/baculovirus insect cell lysate (control
lysate I) or a lysate from High Five cells (control lysate II,
0.1 μg/ml) was used as control antigen for the system of
production of the L1 VLPs in experiments performed to
determine specificity of the VLP responses.
Cytokine induction assays
PBMC (at a final concentration of 1.5×106/ml) were
incubated in the absence or presence of PHA-M (1:100),
Influenza virus (1:100), VLPs from HPV-16, -18, -31, and -53
(2.5 μg/ml) for 3 days at 37 °C and 6% CO2 in RPMI-1640
(Gibco, Invitrogen Life Technologies, Carlsbad, CA) supple-
mented with penicillin/streptomycin (100 μg/ml/100 U/ml,
Gibco, Invitrogen), Glutamine (2 mM), HEPES buffer
(10 mM), and 10% FCS (Gibco, Invitrogen). Cell free
supernatants were harvested and frozen at −20 °C. As described
above for the lymphoproliferation assays, a Sf-9/baculovirus or
High Five cell insect cell lysate (0.1 μg/ml) was used as a
control antigen in experiments performed to evaluate specificity
of the VLP responses.
Cytokine determinations
Supernatants from the cytokine induction assay were thawed
and tested in duplicate wells for IFN-γ, IL-10 and IL-5 by
ELISA (Endogen, Woburn, MA), following manufacturers'
instructions. The lower levels of detection for IFN-γ, IL-10 and
IL-5 were 15.6, 7.8 and 6.4 pg/ml, respectively. Levels lower
than the lowest detection levels were considered arbitrarily as
half of the lowest detection level (7.8, 3.9 and 3.2 pg/ml,
respectively).
5-Bromodeoxyuridine (BrdU) labeling and flow-cytometric
analysis
This assay was performed as previously described (Pinto et
al., 2003). Briefly, BrdU incorporation into CD4 and CD8 T
cells from a subset of six vaccine recipients was determined
before the initial immunization (i.e., at month 0) and after the
second or third immunization (i.e., at months 2 or 7,
respectively). PBMC cultured for 5 days at 37 °C in the
presence of L1 VLPs (2.5 μg/ml), control baculovirus lysate,
and control media were incubated with 10 μM BrdU (Sigma)for the final 4.5 h of culture. Cell surface staining was
performed with either anti-human CD3 PE (Becton Dickinson,
San Jose, CA), anti-human CD4 PC5 (Beckman Coulter,
Fullerton, CA), or anti-human CD8 ECD (Beckman Coulter)
antibodies. The stained cells were treated with OptiLyse C
lysing solution (Beckman Coulter) for 10 min at room
temperature, followed by incubation, for 15 min at 37 °C,
with 1% paraformaldehyde and 1% Tween-20 in PBS, to fix and
permeabilize the cells. Cellular DNA in the permeabilized cells
was partially digested, for 30 min at 37 °C, with DNase-I
(Boehringer-Mannheim, Roche Applied Science, Indianapolis,
IN) in DNase buffer (PBS with 4.2 mM MgCl2, pH 5) and then
was stained, for 30 min, with anti-BrdU FITC (Becton
Dickinson) antibody in PBS containing 1% bovine serum
albumin and 0.5% Tween-20. Cells were washed twice before
flow-cytometric analysis. A target of approximately 100,000
CD3+ T cells was collected. Samples were stained and analyzed
in parallel with unlabeled cells (without BrdU) from the same
individual, and this value was subtracted from the value
obtained for BrdU-labeled cells. Data are presented as the
percentage of cells in the specific lymphocyte pool that are
BrdU positive. The high sensitivity (0.01% BrdU+ cells) of this
assay derives from analysis of large numbers of events (50,000–
100,000), strong anti-BrdU-antibody staining of labeled cells,
and low background binding of anti-BrdU antibody to
unlabeled cells (Lempicki et al., 2000).
Neutralization assay
HPV-16, HPV-18, and HPV-31 neutralizing antibody titers
were determined using a pseudovirus-based neutralization
assay performed as previously described (Pastrana et al.,
2004). Briefly, diluted pseudovirus (HPV-16, HPV-18, HPV-
31, and BPV) carrying a secreted alkaline phosphatase (SEAP)
reporter gene was combined with diluted serum for 1 h at
4 °C. This mixture of pseudovirus–antibody mixture was
incubated with preplated 293 TT cells for 72 h, at 37 °C. At
the end of the incubation, supernatant was harvested and
clarified. The SEAP content in the clarified supernatant was
determined using the Great EscAPe SEAP Chemilumines-
cence Kit (Becton Dickinson) as manufacturer's directions.
Twenty minutes after the substrate was added, samples were
read in a chemiluminescence reader (Molecular Devices,
Sunnyvale, CA). Serum neutralization titers were defined as
the reciprocal of the highest dilution that caused at least a 50%
reduction in SEAP activity. A serum was considered to be
positive for neutralization in the HPV-16, HPV-18, or HPV-31
assay if it was neutralizing at a dilution at least 4-fold higher
than the titer observed in the BPV control neutralization assay.
Neutralizing activity against HPV-53 was not determined
because SEAP HPV-53 VLPs were not available. Undetect-
able antibody levels were considered 0. As shown in Table 4,
sera from all HPV-16 recipients had detectable anti-HPV-16
neutralizing antibodies after vaccination. Median antibody
titers in vaccine recipients (n=11) before vaccination were 0
(mean 28±94, ranges 0–313). Only one of the 11 vaccine
recipients had detectable neutralizing antibodies at entry for
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pectively. Following vaccination, median antibody levels were
511 and 4929 at months 2 and 7 (means of 6927±16,699;
ranges 168 to 56,632 and of 12,663±15,060; ranges of 997 to
55,930), respectively. Sera from vaccine recipients had no
detectable anti-HPV-18 neutralizing activity before and after
vaccination. Median anti-HPV-31 neutralizing titers was 0 at
month 2 after vaccination (mean of 36±73, ranges 0 to 247)
and 50 at month 7 (mean of 250±438, ranges 0 to 1248) after
vaccination. HPV-31 neutralizing activity was detectable in 5
and 7 of the vaccine recipients at month 2 and 7, respectively.
This activity was detectable in the serum samples with the
highest median HPV-16 neutralizing titers (median HPV-16
antibody titers in sera with HPV-31 neutralizing activity=
9386, ranges 1223–56,632 versus median HPV-16 antibody
titers in sera with undetectable HPV-31 neutralizing activity=
997, ranges 168–2271).
Median antibody titers in placebo recipients (n=5) at
enrolment, months 2 and 7 were 0 (undetectable levels for all
placebo recipients) for any of the types tested.
Statistical analysis
We defined responders as individuals who fulfilled the
following criteria: (1) a minimum of 2-fold increase in response
(measured as stimulation index-SI-for lymphoproliferation
assay and pg/ml for cytokines) seen at month 2 relative to
month 0, (2) a minimum response at month 2 of 2-fold relative
to media control (SI>2.0 for lymphoproliferation assay) or
twice the lowest detectable level of the assay (for cytokines),
and (3) ratio of responses at month 2/month 0 for VLP greater
than that for the control lysate. This type of definition accounts
for the variability on the VLP responses of these assays and has
been used in other vaccine studies (Kang et al., 2004).
When evaluating responses to influenza, the first two criteria
were applied. Based on the above definition, percent responders
were estimated for each HPV type and for influenza. 95%
confidence intervals (95% CI) were computed using exact
methods. The percent of women responding to more than one
heterologous HPV type was also estimated, and compared
between responders and non-responders to HPV-16 VLP; p values
were obtained based on the Fisher's exact test. For these estimates,
only the lymphoproliferation, IFN-γ, and IL-10 assays were
considered, given the low levels of IL-5 responses observed.
Wilcoxon signed rank test was used to determine statistical
differences between median to antigens before and after vaccina-
tion. To determine the relationships between responses to the
different VLPs following vaccination, Spearman rank correlations
were computed, along with their corresponding p values.
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